Advertisement

Advertisement

2023 NCCN Annual Congress: Hematologic Malignancies

By Chase Doyle / January 25, 2024 / 2023 NCCN Annual Congress: Hematologic Malignancies

ALL in Adults: Trial Updates and Clinical Considerations for Selecting Consolidation Therapy

Although pediatric patients with acute lymphoblastic leukemia (ALL) have seen a dramatic improvement in long-term survival rates over the past 40 years, from approximately 10% to over 95%, adults aged...

By Chase Doyle / November 25, 2023 / 2023 NCCN Annual Congress: Hematologic Malignancies

Optimizing Treatment Selection for Newly Diagnosed and Secondary AML: Focus on Cytogenetic and Molecular Data

Greater understanding of biological disease factors in acute myeloid leukemia (AML) has led to more effective and personalized treatment options. At the 2023 National Comprehensive Cancer Network (NCC...

Advertisement

Advertisement

Apr

28

Today In Oncology

Adjuvant Pembrolizumab in Renal Cell Carcinoma: Overall Survival in KEYNOTE-564

Combined ICI and VEGF Inhibitor Trials in Cancer Cardiovascular Eligibility Criteria and Adverse Event Reporting

Risk of T-Cell and Second Primary Malignant Neoplasms After CAR T-Cell Therapy

Lack of Research Focused on Older Adults With Cancer May Be Contributing to Disparities in Care

Breast Cancer Survivors: Relationship Satisfaction and Emotional and Physical Well-Being

Advertisement

© 2024 HSP News Service, L.L.C.

Designed by Harborside